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Childhood ITP is often considered to be a relatively mild haematological disorder, 
with only a minority of patients requiring treatment for troublesome bleeding. Over 
recent years, wider effects of the condition have been identified in some adults, 
particularly relating to fatigue and cognitive impairment. In this study, we sought to 
investigate such effects in a group of children with ITP and further our understanding 
of their psychological profile. Children attending routine haematology outpatient 
clinics and their parents were asked to complete standardised questionnaires 
designed to assess a range of psychological and cognitive factors. Although most 
children had scores within the normal range, a significant proportion had difficulties 
with fatigue, emotional and behavioural symptoms and executive functioning. 
Quality of life and subjective evaluation of the illness (appraisal) correlated 
significantly with each of these domains, but bleeding severity and platelet count did 
not. Our findings provide valuable insight into the broader impact of childhood ITP, 
which could aid in providing holistic care, potentially contribute to decisions 
regarding medical treatment, and guide future research. 
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Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder, 
characterised by an isolated thrombocytopenia which results in an increased risk of 
bleeding. In children, bleeding symptoms are usually mild and the spontaneous 
remission rate is high, with 75-80% of children recovering within 12 months of 
presentation (Imbach et al, 2006; Heitink-Pollé et al, 2014). In light of this, most 
children with ITP in the UK do not receive therapy directed at raising the platelet 
count, but are managed on an expectant “watch and wait” policy (Grainger et al, 
2012). International consensus guidelines on the management of childhood ITP 
(Provan et al, 2010) advise initiating treatment based largely on bleeding symptoms, 
along with consideration of lifestyle factors (particularly the restriction of activities 
with a high risk of head injury). 
Studies in adults with ITP have identified a broader impact of the condition. Fatigue 
is now well-established as a symptom of adult ITP (Zhou et al, 2007; Mathias et al, 
2008; Sarpatwari et al, 2010; Newton et al, 2011) and a range of potential 
mechanisms have been proposed to account for its occurrence (Hill & Newland, 
2015). Other studies have shown a significant reduction in health-related quality of 
life (HRQoL) (reviewed by Trotter & Hill, 2018) and also an association between 
adult ITP and mild cognitive impairments (Frith et al, 2012).
Studies of children have suggested that fatigue may also be a feature of childhood 
ITP (Blatt et al, 2010; Sarpatwari et al, 2010) and have described a negative impact 
of ITP on health-related quality of life (HRQoL) (reviewed by Trotter & Hill, 2018). 
Anecdotally, some parents also report mood changes or behavioural problems in 
their children following a diagnosis of ITP. However, to date no study has used 






























































standardised measures of fatigue or emotional and behavioural symptoms to fully 
explore these issues. Furthermore, a recent review of the management of childhood 
ITP has called for research into the cognitive profile of patients with the condition 
(Cooper, 2014).  
We, therefore, sought to investigate fatigue, emotional and behavioural symptoms, 
and executive functioning (an aspect of cognition involving planning, organisation 
and self-regulation) in a group of children with ITP, using a range of validated age-
appropriate measures. Our aim was to better understand the psychological profile of 
children with ITP, not only to help inform holistic care for such children and their 
families, but also to further the debate on factors that could influence decisions on 
whether or not to treat a child with ITP. 
Methods
The study was approved by Royal Holloway University, the National Research 
Ethics Service and local Research & Development Departments and was conducted 
at paediatric haematology clinics at two NHS hospitals in London. Eligible children 
were identified by the consultant haematologists running these clinics. The Chief 
Investigator then approached these families at a routine clinic appointment or over 
the phone following the appointment to discuss the study. The potential participants 
were not known to the Chief Investigator prior to commencement of the study. Both 
the children and their parents were provided with written information and were given 
the opportunity to ask further questions. Informed consent was obtained prior to 
enrolment. The families were then given questionnaire measures to complete, with 






























































the option to complete on site or return by post. Demographic and clinical data were 
obtained from medical records for the same clinic visit. 
Participants 
Children with ITP attending outpatient appointments during a specified 6-month 
period were eligible for the study. Participants were approached if they had persistent 
ITP (3-12 months duration) or chronic ITP (>12 months duration). Children had to 
be at least 4 years old to be included in the study and were eligible to complete self-
report measures from the age of 5 years.  
Children were excluded if they had developed ITP as a result of a bone marrow or 
solid organ transplant, or if they had another medical condition that was poorly 
controlled at the time of the study. Families with a poor command of English were 
excluded if an interpreter was not already present in the clinic, or if language 
translations were not available in the research measures. 
Clinical data
The following clinical information was obtained: age of patient, time since diagnosis, 
platelet count at time of consent to participate, bleeding severity (using the grading 
system in Provan et al, 2010), current and previous treatments aimed at increasing 
the platelet count, side effects of any treatment, details of any other conditions, and 
the occurrence of an intracranial haemorrhage at any stage. Clinicians also gave a 
subjective rating of severity of illness and were asked to comment on any significant 
change in the severity of the child’s ITP since the previous clinic visit. 






























































Psychological and cognitive measures 
Measures were chosen that were appropriate to the population being studied (with 
reported acceptable or good reliability), were relatively brief to complete and had the 
potential to capture both parents’ and children’s perspectives. The questionnaires 
given to each child and parent varied depending on the age of the child, with younger 
children completing fewer measures (detailed in Table I). 
In addition to these measures, parents and children were asked to appraise the 
severity and impact of their ITP, by means of up to three (for children) or five 
questions (for parents) using a bespoke 5-point Likert visual analogue scale and a 
space for free comments (Appendix 1). 






























































Table I.  Standardised measures used in the study.
Measure Completed by parent 
/ child (age)
Reference Score range Clinically 
significant 
difficulties  
Strengths and Difficulties Questionnaire 
(SDQ), subscales: 
        Total difficulties score 0-40 Score 17 or over
        Emotional symptoms score
Parent &
Child (11-16 years)
Goodman et al, 
1997 0-10 Score 5 or over
Pediatric Quality of Life InventoryTM 




Varni et al, 
2002
0-100 77.7 or lower  
(-1SD from 
population mean)
Behaviour Rating Inventory of Executive 
Functioning (BRIEF)




T score above 65
Kids ITP Tools (KIT)
(Quality of Life measure)
Parent &
Child (5-16 years)
Klaassen et al, 
2007, 2013
0-100 Not available































































The Chief Investigator performed the data analysis and the clinical team was not 
involved in this, in order to avoid potential bias. Scores on all measures were 
examined for normality, outliers and inconsistencies. A square root transformation 
was applied to the platelet count due to skew. Missing values were treated in 
accordance with instructions for individual scales. The data were analysed using 
Statistical Software for Social Scientists (SPSS) version 21. T tests were used to 
compare scores with available norms (see results section). For the Strengths and 
Difficulties Questionnaire (SDQ) only children aged between 5 and 15 years were 
included in this comparison, as normative data were only available for this age 
group. Bivariate correlations were used for exploratory analysis. Alpha value for 
significance was considered as p < 0.05. 
Results
Forty-six families were eligible and approached within the period of the study. All 46 
families consented to participate. Ultimately, at least one questionnaire was returned 
from 37 families (35 parent questionnaires and 35 child self-report questionnaires), 
an 80% return rate. 
Demographics and clinical data
Data on the 37 children from whom completed questionnaires were returned are 
recorded in Table II. Most children had chronic ITP and were not receiving treatment 
at the time of the study. Co-morbid conditions were all judged clinically to be well-
managed and stable. Bleeding severity as rated by clinicians was generally low, with 






























































only one patient rated as moderate bleeding severity; the remaining children had 
minor/mild bleeding or no bleeding at the point of study entry. 
Table II.  Demographic & clinical data.
Children with ITP (N=37)
Gender
        Male 20
        Female 17
Age in years, mean (range) 9.8 (4.8-16.4)
Nature of ITP
       Persistent 5 (14%)
       Chronic 32 (86%)
Time since diagnosis in months, median (range) 28 (3-96)
Current platelet count x109/l, median (range)a




       Active treatmentc 6 (16%)
       Previous treatmentd 19 (51%)
Patients with other conditionse 8 (22%)
Previous intracranial bleed 1
a 7 patients had normal platelet counts on the day of entry into the study, due to either spontaneous 
improvement since the last clinic visit (4) or recent/current treatment (3)
b Only treatments aimed at increasing the platelet count included (i.e. tranexamic acid not included)
c  Intravenous immunoglobulin (2), mycophenolate mofetil (2), rituximab (1), eltrombopag (1)
d  Intravenous immunoglobulin (19), prednisolone (12), anti-D (2), rituximab (3), romiplostim (2)
e Allergic rhinitis (2), asthma (2), coeliac disease (1), congenital talipes equinovarus (1), diabetes 
mellitus (1), Evans syndrome (2), Klinefelter syndrome, mild IgA and IgM deficiency (1)






























































Table III. Summary of scores on psychological and cognitive measures, with comparisons to 
normative data.










     Total difficulties  















     Total fatiguea
BRIEF













SDQ, Strengths and Difficulties Questionnaire; MFS, Multidimensional Fatigue Scale; BRIEF, Behaviour 
Rating Inventory of Executive Function; GEC, Global Executive Composite
* Study scores significantly different from normative comparison scores 
a Lower scores on the PedsQLTM MFS indicate higher levels of fatigue
b Completed by parents only































































Scores from the measures used to ascertain a psychological profile for the sample of children 
with ITP are displayed in Table III. 
Emotional and behavioural symptoms (assessed by the SDQ) 
T-tests for parent ratings on the SDQ compared with a normative group (using published data 
from Meltzer et al, 2000) showed significant differences for both the Total Difficulties and 
Emotional Symptoms scores (t (10328) = 2.41, p = .02, and t (10328) = 3.81, p < .001, 
respectively). Although most children from the total sample had scores comparable to the 
normal population, over a quarter of the children (25.7%) were rated by their parents to have 
problems with emotional symptoms that were of high or very high severity (Figure 1).  In the 
normal population only 10% of the population would be expected to have scores in this 
region (Goodman & Goodman, 2011). Interestingly, child-reported scores for both Total 
Difficulties and Emotional Symptoms scores were not significantly different from normative 
values (t (4240) = 1.29, n.s.; t (4240) = 0.66, n.s.). 
Figure 1: Emotional Symptom scores (parent ratings)


























       ■ cases rated as high or very high severity        --------  clinical cut off for high or very high severity































































There were significantly lower scores on the PedsQLTM MFS for this sample compared with 
those for healthy controls (from data published by Panepinto et al., 2014), for both parent and 
child ratings (t (291) = 9.42, p < 0.01; t (241) = 4.83, p < 0.01, respectively). This indicates 
that children with ITP in this sample were reported as having higher levels of fatigue 
compared with healthy children. Examination of frequencies of parent reports, shows that 24 
children had scores that were at least one standard deviation lower than the normative mean, 
a level proposed (by Varni et al, 2007) as a useful cut off for at risk groups. 
Executive functioning 
In terms of executive functioning, 19.4% of the sample (6 children) were rated by their 
parents to have a high amount of difficulties (See Figure 3), compared with an expected 6.6% 
in the general child population (based on data from Gioia et al, 2000). The mean score for 
Global Executive Composite (GEC) was significantly higher than the norms for this measure, 
(t (1448) = 2.36, p<0.05), indicating that children with ITP had more difficulties with 
executive functioning than the general child population. 






























































Figure 2: Executive function scores, showing clinically significant values 





















Association between variables 
Significant correlations were found by bivariate analysis between the three main variables 
assessed in the study: emotional and behavioural symptoms (as measured by the SDQ), 
fatigue (PedsQLTM MFS) and executive functioning (GEC, within BRIEF) as follows: Total 
Fatigue with SDQ Total Difficulties, r (32) = -0.52, p<0.01; Total Fatigue with GEC, r (29) = 
0.59, p<0.01; GEC with SDQ Total Difficulties, r (29) = 0.81, p<0.01. Lower QoL scores, as 
measured on the Kids ITP Tools were associated both with higher Emotional Symptoms 
scores (parent: r (31) = 0.40, p=0.05; child: r (14) = 0.67, p<0.01), parent-rated SDQ Total 
Difficulties scores (r (31) = 0.39, p=0.05) and higher rates of child-reported fatigue (r (22) = 
0.69, p<0.01). Of note, none of these measures (emotional and behavioural symptoms, 
fatigue, executive functioning or QoL) correlated significantly with bleeding severity or 
platelet count. 
      ■ cases rated as having a high amount of  difficulties         ------  cut off for clinical significance






























































Appraisal of disease severity  
The visual analogue scale that was used to explore appraisal (subjective evaluation of the 
condition) was shown to have good internal consistency for the parent scale (α = 0.81). The 
child scale showed a poor level of reliability (α = 0.65). Clinicians, parents and children had 
significantly different ratings of severity of the ITP, with clinicians rating the condition as 
least severe and parents as most severe (F (2, 52) = 14.95, p < 0.001). On the Likert scale of 
0-5 (5= most severe), the clinicians’ mean rating of severity of illness was 1.28, compared 
with 2.82 as rated by parents and 1.94 for child ratings. Neither platelet count nor bleeding 
severity correlated with any of the three subjective ratings of severity. Subjective rather than 
objective severity correlated better with the psychological measures in this study and all 
appraisal variables were associated with at least one psychological variable. Parents’ ratings 
of both their own ability to cope and their child’s ability to cope correlated with their ratings 
of their perceived child’s quality of life (r (30) = 0.53, p<0.01 and r (30) = 0.45, p<0.01, 
respectively). 
In the free comments sections of the measures, 5 parents reported that they were concerned 
by the uncertainty around the illness and its prognosis, 11 commented on its risk management 
(including restricting activities) and 6 were bothered by the appearance of bruising caused by 
the condition. Thirteen children commented on the impact that ITP has in some way on their 
life, for instance: “not knowing how bad it can get and when, if ever, it can go away”, “the 
platelet count worries me a lot”, “it means I am different from my friends”, and “I’m not able 
to play with my friends”. Two children commented that they were worried about the blood 
tests.  































































This is the first study to investigate the psychological profile of children with ITP using 
validated, standardised, age-appropriate measures. Our results demonstrate that children with 
ITP reported more difficulties with fatigue, emotional and behavioural symptoms and 
executive functioning when compared to healthy children. Although most children in the 
study were functioning at levels similar to the normal population, there were higher 
proportions of children with clinically significant levels of difficulty in each category. The 
findings regarding fatigue are congruent with those in adults with ITP (Zhou et al, 2007; 
Mathias et al, 2008; Sarpatwari et al, 2010; Newton et al, 2011) and confirm earlier reports 
from child surveys (Blatt et al, 2010; Sarpatwari et al, 2010). The findings relating to 
emotional and behavioural symptoms add to research showing a range of increased 
difficulties in children with other chronic health disorders (Barlow & Ellard, 2006; Spencer et 
al, 2009), as well as in adults with ITP (Mathias et al, 2008). Cognitive impairment has also 
been demonstrated in adults with ITP (Frith et al, 2012) and our study suggests that ITP may 
impact on an aspect of cognition (namely, executive functioning) for some children with this 
condition as well. 
Interestingly, in our study, clinical severity (as assessed by bleeding score and platelet count) 
did not predict problems with fatigue, emotional and behavioural symptoms, executive 
functioning or quality of life. It should be noted that bleeding severity was generally low and 
the mean platelet count was relatively high for chronic ITP, but there was a variation in 
platelet counts.  The lack of correlation between platelet counts and fatigue differs from some 
adult studies reporting more fatigue with lower counts (Newton et al, 2011; Kuter et al, 
2012). However, there are other studies in adults with similar findings to our own, 
demonstrating a lack of correlation between clinical severity and either fatigue (Sarpatwari et 






























































al, 2010; Zhou et al, 2007), or quality of life (Neunert et al, 2009). These combined findings 
suggest that other factors associated with the condition, beyond clinical severity, may impact 
on the psychological well-being of patients with ITP. 
A recent review proposed a variety of potential causes for fatigue in adult ITP, including the 
pro-inflammatory disease state (leading to neuro-endocrine disturbance), iron deficiency from 
bleeding, side effects of medication, reduction in activity (due to lifestyle restrictions) and 
other psychosocial factors (Hill & Newland, 2015). Our study found a significant relationship 
between fatigue, emotional and behavioural symptoms and difficulties in executive function, 
in keeping with existing but limited research into these variables (Swain, 2000; Emerson et 
al, 2005; Goretti et al, 2012). It may well be that the mechanisms causing problems in each of 
these variables in ITP are the same, but this requires further study. It is also tempting to 
hypothesise that the emotional-behavioural and cognitive effects are mediated through 
fatigue; however, not all patients affected on the emotional-behavioural and cognitive 
measures (SDQ and BRIEF) scored abnormally on the multidimensional fatigue scale. It 
seems likely that there is a complex interaction between fatigue, emotional and behavioural 
symptoms and difficulties in executive function, and it remains a challenge for any research 
examining these variables to separate their unique and combined contributions.
An additional dynamic in childhood conditions is the parent-child interaction and the 
potential for multiple differing perspectives on the severity and impact of the disease. Of note 
in our study, in contrast to objective assessment of disease severity, subjective assessment 
(particularly by parents, but also by children) did correlate with measures of fatigue, 
emotional and behavioural symptoms and quality of life.  This may indicate that some 
families are more affected by these outcomes than by bleeding severity. Alternatively, a 






























































parent’s or child’s appraisal of disease severity may be one of the factors influencing these 
outcomes. The relationship between appraisal of disease, fatigue and psychological outcomes 
is also likely to be a complex one and requires further investigation.
Whilst this study provides a useful insight into the psychological well-being of children with 
ITP, there are some limitations. As a cross-sectional study, it is not possible to draw firm 
conclusions regarding the causes of our findings or the impact of different treatment 
approaches. Further, the sample size was relatively small and drawn from two specialist 
centres. It therefore may not have represented the wider population of children with persistent 
/ chronic ITP. Also, although the return rate was generally good and indeed higher than 
expected for a study of this nature, it is possible that the families who did not return the 
questionnaires represented a different group. Finally, several of the children had other 
medical conditions; although these were considered to be inactive or well-controlled at the 
time of the study, it is possible that they influenced the results.
In summary, this study has demonstrated significant non-bleeding effects of childhood ITP, 
in terms of fatigue, emotional and behavioural symptoms and difficulties in executive 
functioning. These effects may not be clearly apparent in any given patient in clinic, 
particularly given their lack of association with bleeding severity or platelet count. 
Appropriate questions to elicit symptoms may, therefore, be required in order to identify 
those who would benefit from a thorough assessment of psychological and educational needs, 
with referral to psychological services where appropriate. This research also broadens the 
debate on whether or not to treat a child with ITP. International consensus guidelines on the 
management of childhood ITP advise initiating treatment based largely on concerns regarding 
bleeding (Provan et al, 2010). Our data highlight the wider impact of the condition, with 






























































effects demonstrated on the abilities of children to function normally. Given that the children 
in this study all had persistent or chronic disease, it is possible that some of them may have 
experienced these effects for many months or even years. It is not yet known whether 
treatment of the disease could reduce these effects, but it would be worth exploring. Quality 
of life studies in ITP have shown conflicting results, with some showing an improvement 
following treatment (Blanchette et al, 2010; Kuter et al, 2012) and others showing no change 
(Bussel et al, 2007, 2015; Grainger et al, 2013) or only an improvement in the parents, rather 
than the children themselves (Klaassen et al, 2012; Mathias et al, 2016). A detailed 
prospective longitudinal study is needed to assess fatigue, emotional and behavioural 
symptoms and difficulties in executive functioning, in which the standardised measures used 
here are applied at several time points in the disease course of a large cohort of children with 
ITP. This may provide more insight into any potential additional benefits of treatment. 
However, in the meantime, it is reasonable to consider the broader impact of childhood ITP 
suggested here, when making a decision to continue to “watch and wait” for a child with 
persistent or chronic ITP. 
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Visual Analogue Scale- Parent/Carer, version 1
How severe would you rate your child’s illness? 
| |  | |  |  |
0 1 2 3 4 5
Not at all severe  Very severe
How much does your child’s ITP affect their life? 
| |  | |  |  |
0 1 2 3  4 5
Has no effect Affects it a lot
 
How much does your child’s ITP affect your life? 
| |  | |  |  |
0 1 2 3  4 5
Has no effect Affects it a lot
How able do you feel to cope with your child’s ITP? 
| |  | |  |  |
0 1 2 3  4 5
Not able to cope at all Completely able to cope
How able do you feel your child is to cope with their ITP? 
| |  | |  |  |
0 1 2 3  4 5
Not able to cope at all Completely able to cope
What part of your child’s ITP bothers you the most? 
………………………………………………………………………






























































Visual Analogue Scale- Child version 7-16 years
How bad/severe is your illness? 
| |  | |  |  |
0 1 2 3  4 5
Not at all severe  Very severe
How much does ITP affect your life? 
| |  | |  |  |
0 1 2 3  4 5
Has no effect Affects it a lot 
How able do you feel to cope with your ITP? 
| |  | |  |  |
0 1 2 3  4 5
Not very able to cope Completely able to cope
What part of your ITP bothers you the most? 
…………………………………………………………………….






























































Visual Analogue Scale- Child version 5-7 year version
How bad is your illness? 
| |  | |  |  |
0 1 2 3  4 5
Not at all bad  Very bad
What part of your illness worries/bothers you the most? 
…………………………………………………………………….
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